Tran­si­ti­on from the In-Vitro Dia­gno­stics Direc­ti­ve to the In-Vitro Dia­gno­stics Regu­la­ti­on (IVDR) on 26 May 2022

As of 26 May 2022, the In-Vitro Dia­gno­stics Direc­ti­ve (PDF) will no lon­ger be in effect. It will be repla­ced by the In-Vitro Dia­gno­stics Regu­la­ti­on (IVDR), which will take imme­dia­te effect in EU mem­ber sta­tes on that date, after a five-year tran­si­tio­nal period.

Under the IVDR, signi­fi­cant­ly more pro­ducts than befo­re will have to under­go a con­for­mi­ty assess­ment pro­ce­du­re with the invol­vement of a noti­fied body. In order to ensu­re a smooth tran­si­ti­on from the Direc­ti­ve to the IVDR, eco­no­mic ope­ra­tors were gran­ted a five-year tran­si­tio­nal peri­od expi­ring on 26 May 2022.

Under IVDR rules, about 80 per­cent of IVD manu­fac­tu­r­ers will be requi­red to invol­ve noti­fied bodies in con­for­mi­ty assess­ment pro­ce­du­res for their pro­ducts, com­pared to just about 15 per­cent under the IVD Directive.

This rai­ses a uni­que pro­blem: many of the noti­fied bodies which were gene­ral­ly eli­gi­ble for con­for­mi­ty assess­ment pro­ce­du­res under the IVD Direc­ti­ve have not (yet) under­go­ne accre­di­ta­ti­on pro­ce­du­res in accordance with Artic­le 31 et seq. of the IVDR and have no inten­ti­on of doing so. At things stand (as of 6 August 2021), only five noti­fied bodies in the EU are accre­di­ted in accordance with the IVDR and will have to con­duct con­for­mi­ty assess­ment pro­ce­du­res under the IVDR . Under the Direc­ti­ve, the­re were most recent­ly 18 accre­di­ted noti­fied bodies. This will unde­ni­ably lead to delays in the cer­ti­fi­ca­ti­on of IVDs, which manu­fac­tu­r­ers must be pre­pared for.

In Sep­tem­ber 2018, the EU Com­mis­si­on published tran­si­tio­nal rules (Imple­men­ta­ti­on Rol­ling Plan) in order to ensu­re a smooth tran­si­ti­on from the IVD Direc­ti­ve to the IVDR. But the­se tran­si­tio­nal rules have crea­ted litt­le reli­ef as far as noti­fied bodies are concerned.

The small num­ber of noti­fied bodies is par­ti­cu­lar­ly attri­bu­ta­ble to the fact that, until 26 May 2021, the com­pe­tent bodies were also busy making pre­pa­ra­ti­ons for the Medi­cal Devices Regu­la­ti­on (MDR) and intro­du­cing the rele­vant struc­tures. In order to avo­id bur­de­ning them with both the­se tasks at the same time, the MDR was ori­gi­nal­ly sup­po­sed to take effect on 26 May 2020, so that the com­pe­tent aut­ho­ri­ties would have two years to make the neces­sa­ry pre­pa­ra­ti­ons for the ent­ry into effect of the IVDR on 26 May 2022. But this time was shor­ten­ed by one year becau­se the ent­ry into effect of the MDR had to be post­po­ned by one year, to 26 May 2021, in light of the coro­na­vi­rus pan­de­mic and the asso­cia­ted chal­lenges for the medi­cal devices indus­try, while the ent­ry into effect of the IVDR has yet to be postponed.

But the tran­si­tio­nal rules do crea­te a cer­tain amount of reli­ef as far as the Euda­med data­ba­se is con­cer­ned. While Euda­med is not yet ful­ly func­tion­al, so that not all rele­vant data can be published in the Euda­med data­ba­se, manu­fac­tu­r­ers will be able to com­ply with their requi­re­ments even wit­hout publi­shing the rele­vant data in Euda­med. It is expec­ted that Euda­med will be ful­ly func­tion­al in 2022.

On the who­le, it will be dif­fi­cult to crea­te ade­qua­te infra­struc­tu­re for imple­men­ta­ti­on of the IVDR by the time it enters into effect on 26 May 2022. It would appear sen­si­ble for the EU to post­po­ne the Regulation’s ent­ry into effect in order to ensu­re an ade­qua­te sup­p­ly of urgen­tly nee­ded IVDs. Other­wi­se, the­re is a risk that the stric­ter requi­re­ments for con­for­mi­ty assess­ment pro­ce­du­res will hin­der or delay deve­lo­p­ment and pla­ce­ment on the mar­ket for a lar­ge num­ber of IVDs due to a lack of noti­fied bodies.

Recom­men­ded actions:

IVD manu­fac­tu­r­ers should seek to under­go con­for­mi­ty assess­ment pro­ce­du­res with accre­di­ted noti­fied bodies right away, if they have not done so alre­a­dy, in order to ensu­re that their pro­ducts recei­ve the neces­sa­ry con­for­mi­ty assess­ment by 26 May 2022. Other­wi­se, the­re is a risk that the­se pro­ducts will have to be taken off the market.


Stay up-to-date

We use your email address exclusively for sending our newsletter. You have the right to revoke your consent at any time with effect for the future. For further information, please refer to our privacy policy.